Navigation Links
InterMune to Present at Citi's 4th Annual Biotech Day
Date:3/30/2009

BRISBANE, Calif., March 30 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Daniel G. Welch, Chairman, Chief Executive Officer and President of InterMune, will present at Citi's 4th Annual Biotech Day in New York City on April 1, 2009 at 10:40 a.m. EDT.

To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF, RECAP, an open-label extension study from CAPACITY, and a research program focused on pirfenidone analog ITMN-520. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
2. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
3. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
4. InterMune Announces Issuance of U.S. Patent for ITMN-191
5. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
6. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
7. InterMune to Present at J.P. Morgan Healthcare Conference
8. InterMune to Present at Deutsche Bank Biotech Boston Confab
9. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
10. InterMune to Release Third Quarter 2008 Financial Results on November 6
11. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2017)... ... January 11, 2017 , ... Photonics industry and STEM advocates ... commending the U.S. Congress and President Obama for their recognition of the importance ... American Innovation and Competitiveness Act (AICA). , The language of the act (S. ...
(Date:1/11/2017)... ... January 11, 2017 , ... ... in clinical settings, it is becoming increasingly clear that the evolution and transmission ... methods, the standard in the study of clinical resistance, has vastly underestimated these ...
(Date:1/11/2017)... ... January 11, 2017 , ... For many fledging startups, ... the challenges young businesses face. With the second installment of Quorum’s newest signature ... Geoff DiMasi, Founder and Principal of interactive design agency, P’unk Ave. , ...
(Date:1/11/2017)... ... January 11, 2017 , ... Advanced Polymer Monitoring ... team. Bernhard Bartylla will lead European initiatives for APMT’s product lines serving polymer ... and ARGEN to European manufacturers and researchers. Bernhard brings significant experience in our ...
Breaking Biology Technology:
(Date:12/12/2016)...  Researchers at Trinity College, Dublin, are opening ... the material with Silly Putty. The mixture (known as ... to sense pulse, blood pressure, respiration, and even ... The research team,s findings were published Thursday ... http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/7/2016)... -- BioCatch , the global leader in behavioral biometrics, ... grew to over 40 granted and pending patents. ... , , The Company,s IP ... System, Device, and Method Estimating Force Applied to a Touch Surface, ... costly hardware components needed to estimate the force and pressure applied to ...
(Date:12/6/2016)... -- Valencell , the leading innovator in performance ... third consecutive year of triple digit growth for its ... a 360 percent increase in companies who have acquired ... by sales of its wrist and ear Benchmark™ sensor ... for hearables for fitness and healthcare applications. ...
Breaking Biology News(10 mins):